Q4 2024 Xenon Pharmaceuticals Inc Earnings Call Transcript

Feb 27, 2025 / 09:30 PM GMT

Release Date Price: $38.31 (-2.02%)

Transcript 10-K8-K

Key Points

Positve

Xenon Pharmaceuticals Inc (XENE) has made significant advancements in its pipeline, including the progress of its ZEU calendar in the Phase 3 epilepsy program.
The company has launched a Phase 3 MDD program and is planning further indication expansion of the ZEU calendar in bipolar depression.
Xenon Pharmaceuticals Inc (XENE) has a strong presence in the epilepsy community, highlighted by its participation in the American Epilepsy Society meeting.
The company has a robust financial position with cash and cash equivalents sufficient to fund operations into 2027.
Xenon Pharmaceuticals Inc (XENE) is expanding its product portfolio through the advancement of early-stage ion channel programs, including promising candidates targeting KV7 and Nav 1.7.

Negative

The company faces challenges in the recruitment and completion of enrollment for its clinical trials, which could impact the timing of data readouts.
There is competition in the KV7 space, with other companies also developing KV7 drugs for bipolar mania, which could impact Xenon Pharmaceuticals Inc (XENE)'s market position.
The company's focus on expanding into bipolar depression and other neuropsychiatric disorders involves risks and uncertainties related to clinical trial outcomes and regulatory approvals.
Xenon Pharmaceuticals Inc (XENE) is experiencing an increase in R&D expenses due to the expansion of its pipeline and multiple ongoing Phase 3 studies.
The departure of Sherry Allen, the Chief Financial Officer, could lead to transitional challenges as the company searches for her successor.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

XENE.OQ - Xenon Pharmaceuticals Inc
Q4 2024 Xenon Pharmaceuticals Inc Earnings Call
Feb 27, 2025 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello, and thank you for standing by this time. I would like to welcome you to the Q4 2024 CNN Pharmaceuticals in earnings conference call. All lines have been placed in view to prevent any background noise. After the speaker's remarks, there'll be a question and answer session. If you would like to ask a question during this time, if you press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press one again.

I would now like to turn the conference over to Chat Fuji. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
---------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.